132 related articles for article (PubMed ID: 9266822)
1. Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16).
Gantchev TG; Hunting DJ
Biochem Biophys Res Commun; 1997 Aug; 237(1):24-7. PubMed ID: 9266822
[TBL] [Abstract][Full Text] [Related]
2. The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex.
Gantchev TG; Hunting DJ
Mol Pharmacol; 1998 Mar; 53(3):422-8. PubMed ID: 9495807
[TBL] [Abstract][Full Text] [Related]
3. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine.
Kim SA; Kwon Y; Kim JH; Muller MT; Chung IK
Biochemistry; 1998 Nov; 37(46):16316-24. PubMed ID: 9819224
[TBL] [Abstract][Full Text] [Related]
4. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
5. Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.
Ritke MK; Allan WP; Fattman C; Gunduz NN; Yalowich JC
Mol Pharmacol; 1994 Jul; 46(1):58-66. PubMed ID: 8058057
[TBL] [Abstract][Full Text] [Related]
6. Covalent attachment of ethidium to DNA results in enhanced topoisomerase II-mediated DNA cleavage.
Marx G; Zhou H; Graves DE; Osheroff N
Biochemistry; 1997 Dec; 36(50):15884-91. PubMed ID: 9398321
[TBL] [Abstract][Full Text] [Related]
7. Dependence of etoposide-induced cytotoxicity and topoisomerase II-mediated DNA strand breakage on the intracellular ionic environment.
Lawrence TS; Canman CE; Maybaum J; Davis MA
Cancer Res; 1989 Sep; 49(17):4775-9. PubMed ID: 2547516
[TBL] [Abstract][Full Text] [Related]
8. Reduced topoisomerase II-mediated DNA cleavage in VP-16 resistant human leukemic cell line.
Saijo Y; Satoh K; Tokue Y; Kumano N; Motomiya M
Anticancer Res; 1991; 11(1):445-8. PubMed ID: 1850222
[TBL] [Abstract][Full Text] [Related]
9. Hyperthermia can reduce cytotoxicity from etoposide without a corresponding reduction in the number of topoisomerase II-DNA cleavable complexes.
Dynlacht JR; Wong RS; Albright N; Dewey WC
Cancer Res; 1994 Aug; 54(15):4129-37. PubMed ID: 8033146
[TBL] [Abstract][Full Text] [Related]
10. Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.
Elsea SH; Westergaard M; Burden DA; Lomenick JP; Osheroff N
Biochemistry; 1997 Mar; 36(10):2919-24. PubMed ID: 9062121
[TBL] [Abstract][Full Text] [Related]
11. The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.
Wang SJ; Peyrollier K; Bourguignon LY
Arch Otolaryngol Head Neck Surg; 2007 Mar; 133(3):281-8. PubMed ID: 17372087
[TBL] [Abstract][Full Text] [Related]
12. The combination of different types of antitumor topoisomerase II inhibitors, ICRF-193 and VP-16, has synergistic and antagonistic effects on cell survival, depending on treatment schedule.
Ishida R; Iwai M; Hara A; Andoh T
Anticancer Res; 1996; 16(5A):2735-40. PubMed ID: 8917380
[TBL] [Abstract][Full Text] [Related]
13. Azatoxin is a mechanistic hybrid of the topoisomerase II-targeted anticancer drugs etoposide and ellipticine.
Cline SD; Macdonald TL; Osheroff N
Biochemistry; 1997 Oct; 36(42):13095-101. PubMed ID: 9335572
[TBL] [Abstract][Full Text] [Related]
14. Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants.
Liu SY; Hwang BD; Haruna M; Imakura Y; Lee KH; Cheng YC
Mol Pharmacol; 1989 Jul; 36(1):78-82. PubMed ID: 2546053
[TBL] [Abstract][Full Text] [Related]
15. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells.
Yang L; Rowe TC; Liu LF
Cancer Res; 1985 Nov; 45(11 Pt 2):5872-6. PubMed ID: 2996763
[TBL] [Abstract][Full Text] [Related]
16. Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity.
Arimondo P; Boukarim C; Bailly C; Dauzonne D; Monneret C
Anticancer Drug Des; 2000 Dec; 15(6):413-21. PubMed ID: 11716434
[TBL] [Abstract][Full Text] [Related]
17. Antitumor agents. Part 235: Novel 4'-ester etoposide analogues as potent DNA topoisomerase II inhibitors with improved therapeutic potential.
Xiao Z; Vance JR; Bastow KF; Brossi A; Wang HK; Lee KH
Bioorg Med Chem; 2004 Jun; 12(12):3363-9. PubMed ID: 15158805
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis of unstimulated human lymphocytes and DNA strand breaks induced by the topoisomerase II inhibitor etoposide (VP-16).
Tronov VA; Konoplyannikov MA; Nikolskaya TA; Konstantinov EM
Biochemistry (Mosc); 1999 Mar; 64(3):345-52. PubMed ID: 10205305
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
[TBL] [Abstract][Full Text] [Related]
20. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
